Dr. Bodei is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10065Phone+1 212-639-5387Fax+1 212-717-3263
Education & Training
University of GroningenPhD, 2007 - 2009- University of PisaResidency in Nuclear Medicine, Cum Laude, 1995 - 1999
University of Pisa Faculty of MedicineClass of 1995
Certifications & Licensure
CT State Medical License 2024 - 2025
NJ State Medical License 2021 - 2025
NY State Medical License 2016 - 2025- American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
- Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver Start of enrollment: 2020 Sep 02
- A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer Start of enrollment: 2021 Sep 14
Roles: Contact
- Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors Start of enrollment: 2024 Jun 03
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 23 citationsDelta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.Joshua A Korsen, Julia A Gutierrez, Kathryn M Tully, Lukas M Carter, Zachary V Samuels
Proceedings of the National Academy of Sciences of the United States of America. 2022-07-05 - 69 citationsJoint EANM/SNMMI procedure guideline for the use ofLu-labeled PSMA-targeted radioligand-therapy (Lu-PSMA-RLT).Clemens Kratochwil, Wolfgang P Fendler, Matthias Eiber, Michael S Hofman, Louise Emmett
European Journal of Nuclear Medicine and Molecular Imaging. 2023-07-01 - 144 citations177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival an...Jonathan R. Strosberg, Martyn Caplin, Pamela L. Kunz, Philippe Ruszniewski, Lisa Bodei
The Lancet. Oncology. 2021-11-15
Journal Articles
- Biodistribution and Radiation Dose Estimates for 68Ga-DOTA-JR11 in Patients with Metastatic Neuroendocrine TumorsSimone Krebs, Lisa Bodei, Diane Reidy, Bradley J Beattie, Wolfgang A Weber, European Journal of Nuclear Medicine and Molecular Imaging
- Blood mRNA Measurement (NETest) for Neuroendocrine Tumors Diagnosis of Image-Negative Liver Metastatic DiseaseIrvin M Modlin, Lisa Bodei, The Journal of Clinical Endocrinology and Metabolism
Lectures
- PRRT neuroendocrine tumor response assessment using blood transcript analysis: The NETest.ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
- Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Authored Content
- Observations from a Biomarker Perspective at ASCO GIFebruary 2020
- Observations from a Biomarker Perspective at ASCO GIFebruary 2020
Press Mentions
Blood Biomarkers Predict Neuroendocrine Tumor Response to Radiopharmaceutical TherapyApril 7th, 2023- ASCO 2021: PSMA-Targeted Radioligand Therapy Improves Survival in Metastatic Prostate CancerJune 3rd, 2021
- A Promising New Therapy for Advanced Prostate CancerJune 3rd, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
